Blue Jet Healthcare Ltd.
BLUEJETHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
12 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 12 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20231118 | 2023-09-30 | yes | |
| TRANSCRIPT | 20240214 | 2023-12-31 | yes | |
| TRANSCRIPT | 20240531 | 2024-03-31 | yes | |
| TRANSCRIPT | 20240812 | 2024-06-30 | yes | |
| TRANSCRIPT | 20241108 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250204 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250517 | 2025-03-31 | yes | |
| TRANSCRIPT | 20250728 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251108 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260217 | 2025-12-31 | yes | |
| TRANSCRIPT | 20260529 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260807 | 2026-06-30 | yes |
BLUEJET
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | standalone |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 573.45 |
| 52-week range | 327.25 – 682.35 |
| Return 1M | -2.66% |
| Return 3M | 8.69% |
| Return 1Y | -14.73% |
| Return 3Y | not reported for this period |
| Return 5Y | not reported for this period |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 293.00 |
| Other income | 15.00 |
| Total income | 308.00 |
| Cost of materials consumed | 179.00 |
| Purchases of stock-in-trade | 0.00 |
| Changes in inventories | -42.00 |
| Employee benefit expense | 20.00 |
| Finance costs | 1.00 |
Ownership — 2026-07-09, and the change from 2026-06-30
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.73 | -0.07 |
| institutions foreign | 0.01 | 0.00 |
| institutions domestic | 0.09 | 0.04 |
| mutual funds | 0.05 | 0.03 |
| public | 0.27 | 0.07 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| TRANSCRIPT | 2026-06-30 | 12 |
Financial statements
Filed results, standalone, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 181.00 | 167.00 | 184.00 | 163.00 | 208.00 | 318.00 | 340.00 | 355.00 | 165.00 | 192.00 | 235.00 | 293.00 |
| Other income | 8.00 | 7.00 | 9.00 | 9.00 | 12.00 | 13.00 | 12.00 | 8.00 | 24.00 | 13.00 | 23.00 | 15.00 |
| Total income | 190.00 | 174.00 | 193.00 | 172.00 | 220.00 | 332.00 | 353.00 | 363.00 | 190.00 | 206.00 | 258.00 | 308.00 |
| Cost of materials consumed | 95.00 | 67.00 | 59.00 | 91.00 | 115.00 | 171.00 | 163.00 | 108.00 | 108.00 | 79.00 | 93.00 | 179.00 |
| Purchases of stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in inventories | -17.00 | 4.00 | 27.00 | -17.00 | -25.00 | -27.00 | -10.00 | 75.00 | -51.00 | 14.00 | 9.00 | -42.00 |
| Employee benefit expense | 13.00 | 13.00 | 14.00 | 15.00 | 15.00 | 15.00 | 16.00 | 17.00 | 19.00 | 19.00 | 18.00 | 20.00 |
| Finance costs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 5.00 | 0.00 | 1.00 | 1.00 |
| Depreciation and amortisation | 6.00 | 8.00 | 8.00 | 3.00 | 5.00 | 5.00 | 5.00 | 6.00 | 6.00 | 6.00 | 6.00 | 7.00 |
| Other expenses | 27.00 | 28.00 | 31.00 | 30.00 | 34.00 | 35.00 | 31.00 | 33.00 | 34.00 | 34.00 | 43.00 | 38.00 |
| Total expenses | 125.00 | 120.00 | 139.00 | 122.00 | 143.00 | 199.00 | 205.00 | 240.00 | 121.00 | 152.00 | 170.00 | 202.00 |
| Profit before exceptional items and tax | 64.00 | 53.00 | 54.00 | 49.00 | 77.00 | 132.00 | 147.00 | 123.00 | 69.00 | 54.00 | 87.00 | 106.00 |
| Exceptional items | 0.00 | -10.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 64.00 | 44.00 | 54.00 | 49.00 | 77.00 | 132.00 | 147.00 | 123.00 | 69.00 | 54.00 | 87.00 | 106.00 |
| Current tax | 15.00 | 13.00 | 12.00 | 10.00 | 18.00 | 32.00 | 37.00 | 30.00 | 18.00 | 12.00 | 22.00 | 26.00 |
| Deferred tax | 1.00 | -1.00 | 3.00 | 2.00 | 1.00 | 1.00 | 0.00 | 2.00 | -1.00 | 2.00 | 1.00 | 1.00 |
| Tax expense | 16.00 | 12.00 | 14.00 | 12.00 | 19.00 | 34.00 | 37.00 | 32.00 | 17.00 | 14.00 | 23.00 | 28.00 |
| Profit for the period | 48.00 | 32.00 | 39.00 | 38.00 | 58.00 | 99.00 | 110.00 | 91.00 | 52.00 | 40.00 | 64.00 | 78.00 |
| Other comprehensive income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 |
| Total comprehensive income | 48.00 | 32.00 | 39.00 | 38.00 | 58.00 | 99.00 | 110.00 | 91.00 | 52.00 | 40.00 | 64.00 | 78.00 |
| Earnings per share, basic | 2.76 | 1.85 | 2.29 | 2.18 | 3.36 | 5.71 | 6.35 | 5.26 | 3.01 | 2.32 | 3.71 | 4.51 |
| Earnings per share, diluted | 2.76 | 1.85 | 2.29 | 2.18 | 3.36 | 5.71 | 6.35 | 5.26 | 3.01 | 2.32 | 3.71 | 4.51 |
Annual results, as filed
| Line | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|
| Revenue from operations | 712.00 | 1,030.00 | 947.00 |
| Other income | 29.00 | 46.00 | 69.00 |
| Total income | 740.00 | 1,076.00 | 1,016.00 |
| Cost of materials consumed | 304.00 | 540.00 | 388.00 |
| Purchases of stock-in-trade | 0.00 | 0.00 | 0.00 |
| Changes in inventories | 10.00 | -79.00 | 48.00 |
| Employee benefit expense | 53.00 | 61.00 | 74.00 |
| Finance costs | 0.00 | 0.00 | 6.00 |
| Depreciation and amortisation | 28.00 | 18.00 | 24.00 |
| Other expenses | 115.00 | 130.00 | 144.00 |
| Total expenses | 511.00 | 670.00 | 683.00 |
| Profit before exceptional items and tax | 230.00 | 406.00 | 333.00 |
| Exceptional items | -10.00 | 0.00 | 0.00 |
| Profit before tax | 220.00 | 406.00 | 333.00 |
| Current tax | 54.00 | 97.00 | 81.00 |
| Deferred tax | 2.00 | 4.00 | 3.00 |
| Tax expense | 56.00 | 101.00 | 85.00 |
| Profit for the period | 164.00 | 305.00 | 248.00 |
| Other comprehensive income | 0.00 | 0.00 | -0.00 |
| Total comprehensive income | 164.00 | 305.00 | 248.00 |
| Earnings per share, basic | 9.44 | 17.59 | 14.29 |
| Earnings per share, diluted | 9.44 | 17.59 | 14.29 |
Balance sheet, as filed
| Line | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|
| Total assets | 964.00 | 1,059.00 | 1,181.00 | 1,418.00 | 1,527.00 | 1,641.00 |
| Non-current assets | 267.00 | 353.00 | 385.00 | 412.00 | 537.00 | 684.00 |
| Current assets | 697.00 | 706.00 | 796.00 | 1,006.00 | 990.00 | 957.00 |
| Property, plant and equipment | 161.00 | 172.00 | 268.00 | 260.00 | 302.00 | 314.00 |
| Capital work-in-progress | 64.00 | 147.00 | 85.00 | 89.00 | 159.00 | 301.00 |
| Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other intangible assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00 |
| Inventories | 148.00 | 130.00 | 178.00 | 264.00 | 197.00 | 187.00 |
| Trade receivables | 206.00 | 177.00 | 212.00 | 350.00 | 312.00 | 339.00 |
| Cash and cash equivalents | 55.00 | 41.00 | 30.00 | 33.00 | 67.00 | 61.00 |
| Total equity and liabilities | 964.00 | 1,059.00 | 1,181.00 | 1,418.00 | 1,527.00 | 1,641.00 |
| Equity | 774.00 | 845.00 | 924.00 | 1,133.00 | 1,256.00 | 1,360.00 |
| Equity share capital | 35.00 | 35.00 | 35.00 | 35.00 | 35.00 | 35.00 |
| Other equity | 739.00 | 811.00 | 889.00 | 1,098.00 | 1,221.00 | 1,325.00 |
| Total liabilities | 190.00 | 214.00 | 257.00 | 284.00 | 272.00 | 281.00 |
| Non-current liabilities | 7.00 | 8.00 | 11.00 | 29.00 | 31.00 | 54.00 |
| Current liabilities | 183.00 | 206.00 | 246.00 | 256.00 | 241.00 | 227.00 |
| Borrowings, non-current | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Borrowings, current | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Trade payables | 57.00 | 30.00 | 67.00 | 89.00 | 41.00 | 57.00 |
Cash flow, as filed
| Line | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|
| Net cash from operating activities | 88.00 | 241.00 | 62.00 | 46.00 | 207.00 | 334.00 |
| Net cash from investing activities | -97.00 | -264.00 | -73.00 | -35.00 | -165.00 | -276.00 |
| Net cash from financing activities | -1.00 | -2.00 | -1.00 | -19.00 | -9.00 | -31.00 |
| Purchase of property, plant and equipment | 80.00 | 173.00 | 45.00 | 80.00 | 125.00 | 0.00 |
| Net increase in cash | -10.00 | -24.00 | -11.00 | -8.00 | 34.00 | 28.00 |
| con:CFO.BEFORE_TAX | 121.00 | 252.00 | 99.00 | 135.00 | 260.00 | 443.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 32.00 | 11.00 | 36.00 | 89.00 | 52.00 | 109.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 0.00 | 60.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_SOLD | 0.00 | 0.00 | 27.00 | 0.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | -219.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-11-01 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 | 2026-07-09 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 86.00 | 86.00 | 86.00 | 86.00 | 86.00 | 86.00 | 86.00 | 86.00 | 0.80 | 0.80 | 0.80 | 0.80 | 0.73 |
| Domestic institutions | 4.28 | 3.70 | 3.03 | 2.14 | 1.74 | 2.02 | 1.33 | 0.94 | 0.04 | 0.05 | 0.05 | 0.05 | 0.09 |
| Mutual funds | — | — | — | — | — | — | — | 0.50 | 0.02 | 0.02 | 0.02 | 0.02 | 0.05 |
| Insurance companies | 0.43 | 0.61 | 0.85 | 0.51 | 0.05 | 0.05 | 0.01 | — | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Foreign institutions | 2.72 | 2.93 | 2.01 | 2.02 | 2.18 | 1.10 | 2.29 | 1.97 | 0.02 | 0.01 | 0.01 | 0.00 | 0.01 |
| Public | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 0.20 | 0.20 | 0.20 | 0.20 | 0.27 |
| Non-institutional | 7.00 | 7.37 | 8.96 | 9.83 | 10.07 | 10.87 | 10.38 | 11.09 | 0.15 | 0.14 | 0.15 | 0.15 | 0.17 |
| Shares outstanding | 173465425 | 173465425 | 173465425 | 173465425 | 173465425 | 173465425 | 173465425 | 173465425 | 173465425 | 173465425 | 173465425 | 173465425 | 189275701 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Akshay B Arora | Key Managerial Personnel | Any other transaction, Remuneration | 74,810,000.00 | 2 |
| Shiven A Arora | Key Managerial Personnel | Any other transaction, Remuneration | 48,320,000.00 | 4 |
| Naresh S Shah | Key Managerial Personnel | Any other transaction, Remuneration | 20,000,000.00 | 2 |
| Karuppannan Ganesh | Key Managerial Personnel | Remuneration | 11,870,000.00 | 1 |
| Payal Shah | Daughter of Director | Any other transaction | 4,200,000.00 | 1 |
| Archana A Arora | Wife of Director | Remuneration | 2,000,000.00 | 1 |
| Sweta Poddar | Key Managerial Personnel | Remuneration | 910,000.00 | 1 |
| Preeti Gautam Mehta | Independent Director | Any other transaction | 850,000.00 | 2 |
| Girish Paman Vanvari | Independent Director | Any other transaction | 800,000.00 | 2 |
| Divya Sameer Momaya | Independent Director | Any other transaction | 450,000.00 | 2 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-08-07 | Q1FY27 | OFFICER | Read the call |
| 2026-05-29 | Q4FY26 | JET HEALTHCARE LIMITED | Read the call |
| 2026-02-17 | Q3FY26 | Read the call | |
| 2025-11-08 | Q2FY26 | OFFICER | Read the call |
| 2025-07-28 | Q1FY26 | OFFICER | Read the call |
| 2025-05-17 | Q4FY25 | OFFICER | Read the call |
| 2025-02-04 | Q3FY25 | Read the call | |
| 2024-11-08 | Q2FY25 | Read the call | |
| 2024-08-12 | Q1FY25 | OFFICER | Read the call |
| 2024-05-31 | Q4FY24 | Read the call | |
| 2024-02-14 | Q3FY24 | Read the call | |
| 2023-11-18 | Q2FY24 | BLUE JET HEALTHCARE LIMITED, JET HEALTHCARE LIMITED | Read the call |
What they said about it, quarter by quarter
| Topic | Q2FY25 | Q2FY26 | Q3FY24 | Q3FY25 | Q3FY26 | Q4FY24 | Q4FY25 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Capex | Our capital expenditure plan remains on track. | And we have seen a few CDMO projects in India where the customer has actually kind of gone ahead and funded some of the CAPEX requirements of the CDMO… | And we were doing capex in Unit 2 in the past 12 months. | The growth this quarter was primarily driven by our new capacity additions in Unit 2. | In terms of CAPEX Update of Unit 3: Our expansion project is nearing completion. | On the manufacturing side, while Mr. VK will take you through the mid-term capex plan but seeing the overall outsourcing trends in the CDMO business, … | As a consequence of this high level of versatility in automation, that has been built into the design of this MPP plant at Mahad, we envisage that the… | The total capex that we envisage for the Vizag project is approximately INR1,000 crores over a period of approximately 3 years. |
| Capital allocation | This quarter, we proudly completed our first ever dividend payout of INR1 per share, amounting to INR173.5 million. | — | — | — | — | — | The Company remains its debt free status, and the Company has declared a dividend of Rs. | This predominantly includes capital work in progress at Mahad and investments what we have made in Vizag in terms of land acquisition. |
| Costs | We aim to use this as an opportunity to produce a key raw material which is currently being imported. | Since it is a critical raw material, it is important to build resilience in the supply chain. | February 09, 2024 Our original plan was to move the production of raw material that we are currently importing to in-house which remains intact in Uni… | And we are also witnessing a stable raw material prices in the last few quarters, and we don't see any significant variance out of raw material prices… | This facility has been designed for one key side chain in our contrast media portfolio, a step that not only improves cost-competitiveness but also pr… | in terms of raw material, we could actually see an overall reduction in the price levels during this year. | We also insulate the business to significant volatility of the prices of this particular raw material, which we were till date importing. | At Mahad Unit 3 site, we are progressing well on the backward integration project for the key raw material within our contrast media portfolio. |
| Debt and cash | Our working capital is at 140 days, down by 7 days compared to Q1. We gencrated a free cash flow before Treasury investment at INR318 million. | — | — | Our working capital for the 9 months increased by INR1,200 million, predominantly due to increase in inventory to produce pharmaceutical intermediate. | — | Coming to working capital, there is a reduction in receivable. | In terms of cash flow and liquidity, cash and treasury investments of Rs. | Cash flow from operating activities stood at INR334 crores. |
| Demand | Demand remains robust, which our Plant 6 capacity will support effectively. | Secondly, if we go to our Q1 call, our view was that for the full year, we should see slight growth on the intermediate business based on the order bo… | Can you talk about the pipeline as well because I think the capex plan looks quite large. | We believe this strategic commitment to R&D will reinforce our leadership position and accelerate product pipeline expansion in the coming years. | The initial capacities under development are aligned with customer demand and long-term business visibility We believe the scale, infrastructure and t… | Confirming our order book for the next 18 months. | In terms of outlook, with strong customer demand visibility, multi-year contracts and capacity headroom, we are confident of sustaining a growth momen… | Over the last few quarters, we have also continued to strengthen our development pipeline and R&D capabilities which we believe will support the compa… |
| Guidance | Also anything said on this call which reflects our outlook for the future, or which could be construcd as a forward-looking statement must be reviewed… | As you are aware, we won't be able to give a guidance, but in terms of the end molecule and API, it is growing. | We expect this block to be validated by Q3 FY ‘25. | Also, anything said on this call, which reflects our outlook for the future, or which could be construed as a forward-looking statement must be review… | Also, anything said on this call, which reflects our outlook for the future, or which could be construed as a forward-looking statement, must be revie… | Also, anything said on this call which reflects our outlook for the future, or which could be construed as a forward-looking statement must be reviewe… | Also anything said on this call, which reflects our outlook for the future, or which could be construed as a forward-looking statement, must be review… | As validation activities convert into commercial supplies and new capabilities progressively ramp up, we expect our investments across manufacturing, … |
| Margin | Our EBITDA stood at INR695 million, and we reported aPAT of INR583 million, our highest ever net profit for a quarter, representing 28% of our total r… | But if I am looking at the impact on EBITDA, one, I understand that there is goods in transit. | Now moving on to profitability, if you look at the gross margin, thanks to the softening of raw material prices, for the nine months we are around 57.… | Our EBITDA at INR1,240 million for the current quarter is higher by 79% quarter-over- quarter and 127% year-over-year. | So, revenue from operations decreased by 40% and EBITDA decreased by 62% and PAT decreased by 39%. | We believe to have strong abilities in capital management with the key ratios of ROCE at 26%, EBITDA at 32% and fixed asset turnover north of 5x. | 3,777 million at a 37% margin, up 65% year-on-year and PAT was at Rs. | Our reported Q4 gross margin is 56% compared to 52% in Q3 and 55% in Q4 '25. |
| People | That means this 120 kI will reach a peak utilization and the revenue recognition in the two quarters? @ BLUE JET HEALTHCARE Blue Jet Healthcare Limite… | Sir, firstly, what was the utilization rate in the PI-API facility in this quarter? | So what are the plans for Mahad and what is the utility or utilisation we are looking for in Mahad? | Have we reached the full utilization for the capacity? | I will answer this question by giving you some perspective about the capacity utilizations. | — | Decent capacity utilization achieved by Q4. Customer offtake continues to track well into FY'26. | I think we are -- as far as contrast media is concerned, we are far away from the peak utilization levels because of the ongoing works from the compan… |
| Pricing | — | — | Fortunately, the pricing of the raw material has favoured us for the company so backward integration will happen by Q3 FY ‘25, that is block number 1. | But in terms of pricing, it would be disproportionately high in U.S., right? | So in this context, just trying to reconcile the low contrast media sales, was there any pricing pressure or any specific volume impact which you woul… | — | Volumes have been remaining stable with improved price realizations. | Our reported revenue from operations in FY26 of INR131 crores is a decline of 2% compared to FY25. This category faced pricing pressure from imports a… |
| Revenue growth | In the contrast media product category, Q2, we reported a growth of 76% ona sequential basis, while it has de-grown by 11% year-over-year basis. | Backward for the CMI and also there are other derivatives that could be used for not just, so backward integration is for bottomline expansion and the… | — | In that context, Shiven, how should we look at the growth for this product more closer to the overall contract media market growth of 7%, 8%? | This also could be a significant strategic needle mover for us, both on the bottom line and also on the top line. | I'll first start with Q4 to talk about key highlights of Q4 and then go to the full year of FY24. When you look at Q4 sales we had a growth of 10% com… | Our performance reflects not just topline growth, but a meaningful improvement in quality of earnings, driven by new capacity additions, operational l… | Then this quarter growth was all led by the existing customer investing product or a 90% growth? |